Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.34 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085731 | 0.82 | NFE2L2 (0.40) | TRIM24TRIM33NFE2L2ALDH1A1KDM4E | |
| SCHEMBL2084716 | 0.80 | KDM4E (0.37) | TRIM24TRIM33NFE2L2ALDH1A1KDM4E | |
| SCHEMBL586118 | 0.80 | NFE2L2 (0.48) | TRIM24TRIM33NFE2L2LMNA | |
| SCHEMBL9004117 | 0.80 | CA2 (0.35) | NFE2L2CA2ALDH1A1KDM4ELMNA | |
| SCHEMBL29248105 | 0.79 | CTRC (0.37) | NFE2L2CA2PLCG1P2RY1CTRC | |
| SCHEMBL22212665 | 0.77 | NFE2L2 (0.39) | TRIM24TRIM33NFE2L2ALDH1A1KDM4E | |
| SCHEMBL2084516 | 0.77 | PLCG1 (0.37) | TRIM24TRIM33NFE2L2ALDH1A1KDM4E | |
| SCHEMBL2082864 | 0.77 | CYP19A1 (0.41) | NFE2L2ALDH1A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL2082081 | 0.77 | NFE2L2 (0.38) | NFE2L2P2RY1KMT2A | |
| SCHEMBL22096813 | 0.76 | ALOX12 (0.49) | NFE2L2CA2ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190112287-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-04-18 | — | — | US | disclosed |
| US-10017491-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017491-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9981939-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981939-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-7935704-B2 | antiproliferative, antitumor agent; fungicide; inhibit eukaryotic cell cycle progression in M phase; rheumatoid arthritis, chronic articular rheumatism, psoriasis, diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, macular degeneration, corneal graft rejection, osteoporosis | NEREUS PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7919497-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919497-B2 | Analogs of dehydrophenylahistins and their therapeutic use | NEREUS PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7674903-B2 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674903-B2 | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof | NEREUS PHARMACEUTICALS, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | BEYONDSPRING PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | BEYONDSPRING PHARMACEUTICALS, INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2003084662-A2 | COVALENTLY FIXED LIGAND SYSTEMS, NON-METALLOCENE SYSTEMS AND CATALYST SYSTEMS, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR POLYMERIZING OLEFINS | CELANESE VENTURES GMBH (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | TRIM24 3622/4885TRIM33 4665/4885NFE2L2 121/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | TRIM24 3622/4885TRIM33 4665/4885NFE2L2 121/4885 |
| US-20070078138-A1 | Analogs of dehydrophenylahistins and their therapeutic use | MKI67, HPGDS, HCCS | TRIM24 3973/4885TRIM33 4439/4885NFE2L2 1138/4885 |
| US-20080221122-A1 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE | HPGDS, DHPS, HCCS | TRIM24 3685/4885TRIM33 4599/4885NFE2L2 784/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | TRIM24 3622/4885TRIM33 4665/4885NFE2L2 121/4885 |
| US-10829470-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | TRIM24 3622/4885TRIM33 4665/4885NFE2L2 121/4885 |
| US-20190112287-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | TRIM24 3622/4885TRIM33 4665/4885NFE2L2 121/4885 |
| US-10017491-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | TRIM24 3622/4885TRIM33 4665/4885NFE2L2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.